| 2026-08-20 | Press release | Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis |
| 2026-08-14 | Press release | Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-08-04 | Press release | Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications |
| 2026-07-21 | Press release | Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries |
| 2026-06-11 | Press release | Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom |
| 2026-05-18 | Press release | Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allot |
| 2026-04-30 | Press release | Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock |
| 2026-04-29 | Press release | Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis |
| 2026-03-03 | Press release | Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis |
| 2026-01-21 | Presentation | Rein Therapeutics Corporate Presentation |
| 2026-01-20 | Press release | Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic |
| 2025-11-06 | Press release | Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells N |
| 2025-11-03 | Press release | Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis |
| 2025-10-09 | Press release | Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibr |
| 2025-09-17 | Press release | Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic |
| 2025-08-19 | Press release | Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis |
| 2025-08-14 | Press release | Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 |
| 2025-07-30 | Press release | Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing |
| 2025-05-27 | Press release | Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF |
| 2025-05-19 | Press release | Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference |
| 2025-05-12 | Press release | Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF |
| 2025-05-01 | Press release | Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in |
| 2025-04-28 | Press release | Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Confe |
| 2025-04-23 | Press release | Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for |
| 2025-04-15 | Press release | Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Cave |
| 2025-01-10 | Press release | Aileron Therapeutics Announces Rebranding to Rein Therapeutics |
| 2024-11-13 | Press release | Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathi |
| 2024-10-31 | Press release | Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-692 |
| 2024-10-12 | Press release | Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in |
| 2024-09-23 | Press release | Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopa |
| 2024-07-30 | Press release | Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference |
| 2024-07-01 | Press release | Aileron Therapeutics to be Included in the Russell Microcap® Index |
| 2024-05-06 | Press release | Aileron Therapeutics to Present at Two Upcoming Investor Conferences |
| 2024-05-03 | Press release | Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million |
| 2024-05-01 | Press release | Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rule |
| 2024-05-01 | Press release | Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmon |
| 2024-03-12 | Press release | Aileron Therapeutics Announces CEO Transition |
| 2024-02-15 | Press release | Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary |
| 2024-02-01 | Press release | Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024 |
| 2023-10-31 | Press release | Aileron Therapeutics Announces Acquisition of Lung Therapeutics |